Actually, Abrahao et al. (2010) have shown that the pro-inflammatory COX-2 metabolite prostaglandin E2 and its EP3 receptor can activate head and neck carcinoma cells to proliferate and is a potential target for preventive approaches. This evidence concerns the gene PTGS2 and head and neck carcinoma.